ID

14355

Description

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01404949

Link

https://clinicaltrials.gov/show/NCT01404949

Keywords

  1. 4/12/16 4/12/16 -
Uploaded on

April 12, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Acute Promyelocytic Leukemia NCT01404949

Eligibility Acute Promyelocytic Leukemia NCT01404949

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
previously untreated patients with a morphologic diagnosis of apl, confirmed by demonstration of t(15;17) using conventional cytogenetics or florescence in situ hybridization (fish), or a positive rt-pcr assay for pml-rar at the subject's local institution.
Description

APL

Data type

boolean

Alias
UMLS CUI [1]
C0023487
age ≥18 years. karnofsky performance status of ≥ 60%.
Description

Age and Karnofsky Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0206065
adequate renal function as demonstrated by a serum creatinine ≤ 2.0 mg/dl or a creatinine clearance of > 60 ml/min.
Description

Renal function

Data type

boolean

Alias
UMLS CUI [1]
C0232804
adequate hepatic function as demonstrated by a bilirubin < 2.0 mg/dl (unless attributable to gilbert's disease) and an alkaline phosphatase, ast, and alt ≤ 2.5 times the upper limit of normal.
Description

hepatic function

Data type

boolean

Alias
UMLS CUI [1]
C0232741
normal cardiac function as demonstrated by a left ventricular ejection fraction ≥ 50% on echocardiogram or muga scan.
Description

cardiac function

Data type

boolean

Alias
UMLS CUI [1]
C0232164
qtc ≤ 500 msec on baseline ecg.
Description

QTc

Data type

boolean

Alias
UMLS CUI [1]
C0860814
negative serum pregnancy test in women of childbearing potential.
Description

Serum pregnancy test negative

Data type

boolean

Alias
UMLS CUI [1]
C0430061
ability to swallow oral medication.
Description

oral medication

Data type

boolean

Alias
UMLS CUI [1]
C0175795
men and women of child-bearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finished.
Description

Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0700589
patients with central nervous system involvement by apl are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice.
Description

Therapeutic radiology procedure

Data type

boolean

Alias
UMLS CUI [1]
C1522449
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment for apl, except tretinoin, which may be given for up to 7 days prior to study entry.
Description

Previous treatment

Data type

boolean

Alias
UMLS CUI [1]
C0420262
active serious infections not controlled by antibiotics.
Description

Communicable Diseases

Data type

boolean

Alias
UMLS CUI [1]
C0009450
pregnant women or women who are breast-feeding.
Description

Pregnant Women

Data type

boolean

Alias
UMLS CUI [1]
C0033011
concurrent active malignancy requiring immediate therapy.
Description

Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1]
C0006826
clinically significant cardiac disease (ny heart association class iii or iv), including chronic arrhythmias, or pulmonary disease.
Description

Heart Diseases

Data type

boolean

Alias
UMLS CUI [1]
C0018799
other serious or life-threatening conditions deemed unacceptable by the principal investigator.
Description

Life Threatening Adverse Event

Data type

boolean

Alias
UMLS CUI [1]
C1517874

Similar models

Eligibility Acute Promyelocytic Leukemia NCT01404949

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
APL
Item
previously untreated patients with a morphologic diagnosis of apl, confirmed by demonstration of t(15;17) using conventional cytogenetics or florescence in situ hybridization (fish), or a positive rt-pcr assay for pml-rar at the subject's local institution.
boolean
C0023487 (UMLS CUI [1])
Age and Karnofsky Performance Status
Item
age ≥18 years. karnofsky performance status of ≥ 60%.
boolean
C0001779 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
Renal function
Item
adequate renal function as demonstrated by a serum creatinine ≤ 2.0 mg/dl or a creatinine clearance of > 60 ml/min.
boolean
C0232804 (UMLS CUI [1])
hepatic function
Item
adequate hepatic function as demonstrated by a bilirubin < 2.0 mg/dl (unless attributable to gilbert's disease) and an alkaline phosphatase, ast, and alt ≤ 2.5 times the upper limit of normal.
boolean
C0232741 (UMLS CUI [1])
cardiac function
Item
normal cardiac function as demonstrated by a left ventricular ejection fraction ≥ 50% on echocardiogram or muga scan.
boolean
C0232164 (UMLS CUI [1])
QTc
Item
qtc ≤ 500 msec on baseline ecg.
boolean
C0860814 (UMLS CUI [1])
Serum pregnancy test negative
Item
negative serum pregnancy test in women of childbearing potential.
boolean
C0430061 (UMLS CUI [1])
oral medication
Item
ability to swallow oral medication.
boolean
C0175795 (UMLS CUI [1])
Contraceptive methods
Item
men and women of child-bearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finished.
boolean
C0700589 (UMLS CUI [1])
Therapeutic radiology procedure
Item
patients with central nervous system involvement by apl are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice.
boolean
C1522449 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Previous treatment
Item
previous treatment for apl, except tretinoin, which may be given for up to 7 days prior to study entry.
boolean
C0420262 (UMLS CUI [1])
Communicable Diseases
Item
active serious infections not controlled by antibiotics.
boolean
C0009450 (UMLS CUI [1])
Pregnant Women
Item
pregnant women or women who are breast-feeding.
boolean
C0033011 (UMLS CUI [1])
Malignant Neoplasms
Item
concurrent active malignancy requiring immediate therapy.
boolean
C0006826 (UMLS CUI [1])
Heart Diseases
Item
clinically significant cardiac disease (ny heart association class iii or iv), including chronic arrhythmias, or pulmonary disease.
boolean
C0018799 (UMLS CUI [1])
Life Threatening Adverse Event
Item
other serious or life-threatening conditions deemed unacceptable by the principal investigator.
boolean
C1517874 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial